Study type: In vitro · Status: Verified against declared source
Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo.
PloS one · 2011
Study scale: Ethical approval was received from the Office for Research Ethics Northern Ireland (ethical approval study number 06/NIR01/11) with all patients providing written informed consent prior to participation.
Abstract only: Open source record
Product or molecular entity relationships
- LL-37: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
LL-37 possesses activities extending beyond its basic bactericidal activity and a large body of work has focused on the immunomodulatory activity of LL-37, which may be as, or more, important than its direct antimicrobial action under physiological conditions [23], [27].
Methods
Not reported in the reviewed source.
Scale or participants
Ethical approval was received from the Office for Research Ethics Northern Ireland (ethical approval study number 06/NIR01/11) with all patients providing written informed consent prior to participation.
Key findings
Pre-treatment of monocytes with LL-37 significantly inhibited LPS-induced IL-8 production and the signalling pathway of associated transcription factors such as NF-κB.
Limitations and uncertainty
Pre-treatment of monocytes with LL-37 significantly inhibited LPS-induced IL-8 production and the signalling pathway of associated transcription factors such as NF-κB.
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.